logo-loader
viewReNeuron Group PLC

ReNeuron Group plc - New Exosome Research Collaboration

RNS Number : 0012R
ReNeuron Group plc
25 June 2020
 

 

25 June 2020

   AIM: RENE

 

ReNeuron Group plc

("ReNeuron" or the "Company")

ReNeuron signs new exosome research collaboration 

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that it has signed a new research evaluation agreement with a major US biotechnology company in connection with the use of the Company's proprietary exosomes for the delivery of novel gene silencing therapeutics.

This latest research collaboration will focus on the use of ReNeuron's human neural stem cell (hNSC) derived exosomes for the delivery of the US biotechnology company's neuroscience therapeutic candidates.  ReNeuron will be responsible for manufacturing exosomes and then loading them with the gene silencing sequences after which the US biotechnology company will evaluate the loaded exosomes.  Assuming positive results, the parties will jointly own the novel therapeutic candidate created for future development. 

The research evaluation agreement is in line with ReNeuron's strategy of partnering its exosome technology as a novel delivery vehicle. This new agreement follows an exosome research collaboration with a major pharmaceutical company announced by ReNeuron on 7 April this year, reflecting the increasing level of industry interest in exosomes. 

ReNeuron has developed exosomes derived from human neural stem cells (hNSC) that have a natural ability to cross the blood brain barrier and can thus be used to deliver therapeutics for diseases of the brain.  The hNSC-derived exosomes can be produced through a fully qualified, xeno-free, scalable process and the clinical-grade hNSC source cell-line ensures consistent exosome product.  The hNSC exosomes can be loaded with a diverse range of potential therapeutics, such as siRNA/mRNA/miRNA, CRISPR/Cas9, antibodies, peptides and small molecules.

Commenting on the agreement, Olav Hellebø, Chief Executive Officer of ReNeuron, said: "We are delighted to be collaborating with this major US biotechnology company in the discovery and development of novel gene silencing-based therapeutics.  This latest exosome collaboration follows our strategy of collaborating and out-licensing our proprietary exosome technology as a novel delivery vector and underlines the potential commercial value of these proprietary nanoparticles." 

                                                                        ENDS

 

Contacts:

 

ReNeuron

 

 

+44 (0) 20 3819 8400

Olav Hellebø, Chief Executive Officer

Michael Hunt, Chief Financial Officer

 

Buchanan (UK Media/Investor Relations)

 

+44 (0) 20 7466 5000

Mark Court, Tilly Abraham

 

Argot Partners (US Media/Investor Relations)

Claudia Styslinger, David Rosen

 

+1 212 600 1902

 

 

Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

Jonathan Senior, Stewart Wallace, Ben Maddison

+44 (0) 20 7710 7600

 

 

N+1 Singer (Joint Broker)

Aubrey Powell, James Moat, Tom Salvesen

 

+44 (0) 20 7496 3000

 

 

 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke.  

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain.  The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCFLFITRTISFII

Quick facts: ReNeuron Group PLC

Price: 115

Market: LSE
Market Cap: £36.63 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ReNeuron's Michael Hunt says key focus now is to build dataset for retinal...

ReNeuron Group PLC's (LON:RENE) Michael Hunt speaks to Proactive London's Andrew Scott on the back of its results for the year to the end of March 2020. He says one of the main highlights has been the continuation of the retinal disease clinical study in the US. A recent update showed the...

3 weeks, 4 days ago